Patents by Inventor Ennio Cavalletti

Ennio Cavalletti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5618823
    Abstract: The use of glutathione (GSH) as chemoprotective agent against neurotoxicity induced by antitumor drugs active on the mitotic fuse is herein described.
    Type: Grant
    Filed: December 22, 1994
    Date of Patent: April 8, 1997
    Assignee: Boehringer Mannheim Italia S.p.A.
    Inventors: Ennio Cavalletti, Sergio Tognella
  • Patent number: 5587382
    Abstract: In the search for novel heteroanalogs of anthracenediones, 6,9-bis[(2-aminoethyl-amino]-benzo[g]isoquinoline-5,10-dione dimaleate (BBR 2778), was selected as the most promising compound. Toxicological studies indicate that BBR 2778 is not cardiotoxic.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 24, 1996
    Assignee: Boehringer Mannheim Italia, SpA
    Inventors: A. Paul Krapcho, Miles P. Hacker, Ennio Cavalletti, Ferdinando C. Giuliani
  • Patent number: 4871528
    Abstract: Pharmaceutical compositions containing unit or separate dosages of 2.5 to 5 grams of reduced glutathione (GSH) and known anti-tumor agents, to be used simultaneously, separately or sequentially in anti-tumor therapy.Compounds of the invention, that can be used both in mono- or polychemotherapy, reach surprising results against tumors, thus avoiding the onset of dangerous side-effects, such as nephrotoxicity induced by cisplatinum, and increasing the long term survival rates.
    Type: Grant
    Filed: October 7, 1987
    Date of Patent: October 3, 1989
    Assignee: Boehringer Biochemia Robin SpA
    Inventors: Sergio Tognella, Michele Tedeschi, Roberto Assereto, Odoardo Tofanetti, Ennio Cavalletti